We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Burning Rock Biotech Ltd | LSE:BNR | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.35 | 0 | 01:00:00 |
TIDMBNR
RNS Number : 8032N
Blenheim Natural Resources PLC
11 August 2017
11 August 2017
BLENHEIM NATURAL RESOURCES PLC
("Blenheim" or the "Company")
Nashwan Investment Update
Further to the announcements made on 30 March 2017 and 27 April 2017 with regard to Blenheim's conditional investment into Nashwan Holdings Limited ("Nashwan"), Blenheim is pleased to confirm that it has been advised by Nashwan that it now holds Convention d'Etablissement permits for its prospective lithium project areas, Menianbala and Djidje, in Bougouni province, Mali.
Nashwan and Blenheim are confident that the final issuance of the Arrête permits, as required under Malian law, which confirm the grant of the exploration licences, will now be granted.
Further announcements will be made in due course detailing the planned work programme over the licence areas and confirming the formal grant of the exploration licenses.
Blenheim and Nashwan have now updated the terms of the Company's investment, such that the Company has taken unconditional ownership of 30 per cent of the issued share capital of Nashwan, with the consideration, being GBP200,000 in cash and the issue of 75,000,000 ordinary shares of 0.1p each in the capital of Blenheim, only becoming payable following the grant of the final exploration licences at both Menianbala and Djidje. GBP100,000 of the GBP200,000 cash consideration is to be invested directly into Nashwan by the vendor to fund prospecting and exploration costs, with no dilution to Blenheim's 30 per cent interest.
Blenheim's Chairman, Chris Ells, commented: "Blenheim is pleased that Nashwan has agreed the establishment conventions for the Menianbala and Djidje licences which will accelerate commencement of the work programme on these two licence areas.
The Company intends to make a further announcement on the work programme in the near future.
Blenheim is now entering an exciting phase in the Company's development as an investor in the fast growing lithium market and we look forward to reporting progress from our burgeoning interests in Mali."
Ends
For further information please contact:
Blenheim Natural +44 (0) 1622 Chris Ells Resources Plc 844601 Colin Aaronson/Jamie Barklem/ Daniel Grant Thornton UK +44 (0) 20 Bush LLP 7383 5100 +44 (0)1483 Nick Emerson SI Capital Ltd 413500 Lucy Williams / Peterhouse Corporate +44 (0) 20 Duncan Vasey Finance Limited 7469 0932 Cornhill Capital +44 (0) 20 Nick Bealer Limited 7710 9610
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FURFFLFFDVFBBBD
(END) Dow Jones Newswires
August 11, 2017 07:10 ET (11:10 GMT)
1 Year Burning Rock Biotech Chart |
1 Month Burning Rock Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions